Yes, Waldencast completed the sale of its Obagi Medical dermatological skincare and aesthetics business to the private equity firm Bridgepoint Group in a major transaction valued at up to $460 million. The strategic divestiture allowed Waldencast to significantly pay down outstanding corporate debt, optimize its balance sheet structure, and transition its core focus toward accelerating the worldwide growth of its remaining flagship beauty asset, Milk Makeup.